JP Morgan Chase’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-27
Closed -$83 7746
2025
Q4
$83 Hold
27
﹤0.01% 7229
2025
Q3
$178 Sell
27
-165
-86% -$1.21K ﹤0.01% 7126
2025
Q2
$1.72K Sell
192
-934
-83% -$7.75K ﹤0.01% 6556
2025
Q1
$7.11K Sell
1,126
-2,003
-64% -$18.7K ﹤0.01% 6373
2024
Q4
$32.3K Buy
3,129
+1,934
+162% +$21.3K ﹤0.01% 6141
2024
Q3
$15.4K Buy
1,195
+782
+189% +$11.5K ﹤0.01% 6291
2024
Q2
$5.72K Sell
413
-1,775
-81% -$201K ﹤0.01% 6361
2024
Q1
$680K Buy
2,188
+1,525
+230% +$406K ﹤0.01% 4605
2023
Q4
$174K Buy
663
+662
+66,200% +$120K ﹤0.01% 5467
2023
Q3
$133 Hold
1
﹤0.01% 6886
2023
Q2
$140 Hold
1
﹤0.01% 6672
2023
Q1
$0 Hold
1
﹤0.01% 7014
2022
Q4
$0 Hold
1
﹤0.01% 6810
2022
Q3
$0 Hold
1
﹤0.01% 6686
2022
Q2
$0 Sell
1
-154
-99% -$41.9K ﹤0.01% 6704
2022
Q1
$31K Buy
155
+138
+812% +$30.3K ﹤0.01% 5953
2021
Q4
$4K Buy
17
+16
+1,600% +$5.14K ﹤0.01% 6442
2021
Q3
$0 Hold
1
﹤0.01% 6661
2021
Q2
$0 Sell
1
-2,947
-100% -$1.34M ﹤0.01% 6491
2021
Q1
$1.71M Sell
2,948
-872
-23% -$545K ﹤0.01% 3832
2020
Q4
$2.18M Buy
3,820
+3,782
+9,953% +$2.13M ﹤0.01% 3419
2020
Q3
$22K Sell
38
-29
-43% -$18K ﹤0.01% 5125
2020
Q2
$38K Buy
+67
New +$49K ﹤0.01% 4911

Other funds holding LYRA

JP Morgan Chase's LYRA Position: Q1 2026 in Review

JP Morgan Chase sold out of LYRA THERAPEUTICS INC (LYRA) in Q1 2026, closing a stake of 27 shares — an estimated $83 sold.

JP Morgan Chase first reported a position in LYRA in Q2 2020 and held it in 23 quarters. The position peaked at $2.18M in Q4 2020. 1 fund tracked by Wall St. Rank holds LYRA as of Q1 2026.

  • JP Morgan Chase reported no remaining LYRA THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
  • JP Morgan Chase sold 27 LYRA THERAPEUTICS INC shares in Q1 2026, an estimated $83.
  • JP Morgan Chase first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 23 quarters.
  • JP Morgan Chase's LYRA THERAPEUTICS INC position peaked at $2.18M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.